Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands.
about
Preparation of 5'-O-(1-Thiotriphosphate)-modified oligonucleotides using polymerase-endonuclease amplification reaction (PEAR)Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systemsMultivalent polymers for drug delivery and imaging: the challenges of conjugationPolysilsesquioxane nanoparticles for targeted platin-based cancer chemotherapy by triggered releaseCo-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation.Using SV119-gold nanocage conjugates to eradicate cancer stem cells through a combination of photothermal and chemo therapies.Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugationNanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer.Biodegradable polysilsesquioxane nanoparticles as efficient contrast agents for magnetic resonance imagingTri-peptide cationic lipids for gene deliveryMore effective nanomedicines through particle designReversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides.Reductively responsive siRNA-conjugated hydrogel nanoparticles for gene silencing.PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery.Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotidesThe delivery of therapeutic oligonucleotidesCellular delivery and photochemical activation of antisense agents through a nucleobase caging strategy.Development of Antisense Drugs for Dyslipidemia.Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapyCellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology.Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis.Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides.Towards artificial metallonucleases for gene therapy: recent advances and new perspectives.Oligonucleotide conjugates for therapeutic applications.New developments in the use of gene therapy to treat Duchenne muscular dystrophy.New Modalities for Challenging Targets in Drug Discovery.Bioconjugates for targeted delivery of therapeutic oligonucleotides.Cellular uptake and intracellular trafficking of oligonucleotidesCell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy.Direct oligonucleotide-photosensitizer conjugates for photochemical delivery of antisense oligonucleotides.Targeting Nanocarriers with Anisamide: Fact or Artifact?Targeted delivery of antisense oligonucleotides by chemically self-assembled nanostructures.Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells.Targeted delivery of a splice-switching oligonucleotide by cationic polyplexes of RGD-oligonucleotide conjugate.SV119-gold nanocage conjugates: a new platform for targeting cancer cells via sigma-2 receptorsMultivalent cyclic RGD conjugates for targeted delivery of small interfering RNA.A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid.Conditional control of alternative splicing through light-triggered splice-switching oligonucleotides.The chemistry and biology of oligonucleotide conjugates.
P2860
Q21559611-C7881C0E-0F44-4DA6-9A55-3E34749DB8B4Q26996159-EAB4D745-44A3-4CC4-9E86-389D2BF20174Q27692689-72C1B9AC-09B7-4129-AC7C-660C7BBDD327Q33693052-168B988E-065B-43C3-BAD2-8BB2A2393550Q33716011-B15B9A72-F219-43E7-ACAB-004F90D3F07EQ34052669-86976BA0-03B6-4617-AEA3-683A202CB1F9Q34389283-5119F81D-FD76-48C7-9A99-7AC050181A17Q34479313-19CE4F61-9BC4-41ED-A553-5D302C26B7D3Q34683486-0C3646FB-FF50-475E-A33D-347D3EFB9E7CQ34845591-1BC0FE97-5D30-4390-BC4F-62FB3D078A98Q35106115-98341F3C-1983-4318-8A23-13D085891D3DQ35122908-EEB55EE8-FB77-423A-AC56-22A35DB954ECQ35131115-1AA9A368-6D4A-47D3-B1F8-7DB3C892722AQ35975665-494D8F84-9EAD-4520-8C03-81A81125FEF7Q36980520-B62C97CA-D4C9-4B25-9F60-B9BA54148BC4Q37015817-C8D6B2D6-7D75-4660-84B2-F17AC5333316Q37210936-70F6CBE6-2952-40F8-AB1C-8C441343B80DQ37376458-2BE800D4-1EA0-44FD-B0E5-D518754A9C7BQ37387192-145C02E6-E127-4FD3-84AA-77C2501ACFA2Q37625480-E600A1EA-2CE3-4401-B631-991E1B904904Q37656119-F3380599-FF17-4DE3-9B06-53AC2F2EDC67Q37850458-852F895C-7F3D-4112-99F2-DC1F4A20E418Q37944929-0D97B350-4CD3-4FB7-B404-9B58954486F2Q37948867-47984D72-0F18-4549-A9A1-5B8465F3240EQ38123854-27D70772-EA27-44BD-994B-3B870C84637EQ38168863-92D5A2FC-99F5-4E1C-8BC6-97838DA6D910Q38289100-65A837CB-65AD-477D-9238-D317ABD615DAQ38301011-E52D12F3-AD3C-4500-8E72-2B5CE1DB0583Q38424377-EF84CCBA-7D56-4A70-A62A-2136EFB88192Q38785651-1B3667AA-A4B5-4784-945F-3E39CDA61B13Q38898015-07722A90-ACE6-44F0-8D4B-9B3246A43E06Q39019352-CE1FB678-839C-44B5-9004-2B17CBCF5C4FQ39129886-F8FB6570-1269-471F-B46D-04C9EA2261D5Q39289664-A2CB327B-A019-46CC-8C0B-F3D800E4B451Q39365338-605FEDC4-E803-4995-BD7A-A7E7FCD7D260Q39437911-A296C0EA-F1D0-4C0C-8D44-3E575130FA03Q39506968-D9835750-9B64-4F20-88CA-0CD99083DADCQ41239615-32501C47-E919-4F2F-8D6F-36B7F94E7C9FQ41264456-BA7BB83F-FB88-4640-B39B-EC3ADABFED71Q42011018-00A90C00-405D-4A7D-A806-22B3B72516F7
P2860
Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Targeted intracellular deliver ...... n with small-molecule ligands.
@en
Targeted intracellular deliver ...... n with small-molecule ligands.
@nl
type
label
Targeted intracellular deliver ...... n with small-molecule ligands.
@en
Targeted intracellular deliver ...... n with small-molecule ligands.
@nl
prefLabel
Targeted intracellular deliver ...... n with small-molecule ligands.
@en
Targeted intracellular deliver ...... n with small-molecule ligands.
@nl
P2093
P2860
P356
P1476
Targeted intracellular deliver ...... on with small-molecule ligands
@en
P2093
Leaf Huang
Rudolph L Juliano
P2860
P304
P356
10.1021/JA102635C
P407
P577
2010-07-01T00:00:00Z